Medtecs International Corporation Ltd. 546

AYR Wellness Inc. (CSE: AYR.A) (OTCQX: AYRWF) ("AYR" or the "Company") today announced the closing of the first transfer of its Ohio operations into wholly-owned subsidiaries of Arboretum Bidco LLC ("Arboretum"), in connection with the Company's previously announced restructuring transactions (the "Restructuring Transactions"). Arboretum, which intends to operate under the trade name "Ayr Wellness", is the entity established by the Company's senior secured noteholders as the designated purchaser

VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a medical technology company focused on minimally invasive treatments for venous disease, today announced that CHS Ltd., one of Canada's established medical technology organizations, has selected ScleroSafe® as the latest addition to its vascular portfolio and entered into an exclusive commercialization agreement dated September 30, 2026, to support the introduction of the technology in Canada.

VANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) ("Vortex" or the "Company") is pleased to announce that, further to its news release dated September 17, 2026, it has completed the acquisition (the “Acquisition”) of the Purchased Assets (as defined below) comprising the Meadows Project located in west-central Saskatchewan near the Alberta border (the "Meadows Project"). The Meadows Project is represented by Saskatchewan Subsur

NEW YORK and WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on October 1, 2026, to six newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to accept

Acquisition of a PharmaChoice Canada-bannered pharmacy in Western Canada completed at a purchase price of $1,300,000, subject to customary post-closing adjustmentsThe acquisition increases PharmaCorp’s operating network to 17 pharmaciesPreviously announced purchase of the prescription files of an I.D.A.-bannered pharmacy in Western Canada completed at a purchase price of $475,000, subject to customary post-closing adjustmentsCanadian Imperial Bank of Commerce acquisition facility increased by $1

Vancouver, British Columbia--(Newsfile Corp. - October 1, 2026) - Numinus Wellness Inc. (OTC Pink: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced that its founders will resume their original executive leadership roles, effective October 1, 2026.Payton Nyquvest, founder and Executive Chair, will return to the role of Chief Executive Officer...

Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company") today announced that it will report its Third Quarter 2026 Earnings Results on Wednesday, October 21, 2026, after the Mexican Stock Exchange (BMV) close. The company also announced that it will hold a conference call on Thursday, October 22, 2026, at 11 a.m. Mexico City Time to discuss its quarterly financial results.

Check out the companies making headlines yesterday:

Boston Scientific released the full $8 million holdback on schedule and with no claimsEscrow release is the third funding catalyst Elutia has delivered in 2026, following the August closings of its Avenue Capital loan facility and SimpliDerm® divestitureThe Company is now fully funded through the first year of the expected NXT-41x launch and into 2029 GAITHERSBURG, Md., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix t

Amazon.com, Inc. (NASDAQ:AMZN) and GoodRx Holdings, Inc. (NASDAQ:GDRX) are signing up Americans for flat-fee prescription plans as health insurance coverage thins, according to a Reuters report on September 29. Amazon charges from $5 a month and GoodRx from $14.99, with both including a range of generic drugs at no extra cost. GoodRx calls its version […]

FOSTER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the closing of its previously announced underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors that so chose, in lieu of shares of Series A common stock, pre-funded warrants to purchase

Encompass Health Corp. (NYSE: EHC) today announced it will report results for its third quarter ended Sept. 30, 2026, after the market closes on Wednesday, Oct. 28, 2026. The Company will host an investor conference call at 10 a.m. ET on Thursday, Oct. 29, 2026, to discuss its results.

BOSTON, Oct. 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on improving the lives of people with rare hematology diseases, today announced that, effective on September 30, 2026, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of

Nektar Therapeutics stock took a hit Thursday despite test results that suggested its drug has long-term benefits for alopecia patients.

Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeutics, Tyra Biosciences, and Oscar Health.

IRVINE, Calif., October 01, 2026--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients with congenital heart disease who require pulmonary valve replacement.

SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx) (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that, in connection with its upsized initial public offering of its common stock, the underwriters have fully exercised their option to purchase an additional 3,937,500 shares of ADARx’s common stock at a price to the public of $17.00 per share. The issuance of the additional shares closed on Oc

PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the appointment of Arnd Christ as chief financial officer and member of the Company’s executive board, effective October 1, 2026. Mr. Christ brings more than two decades of financial leadership in

The company is constantly thinking big.

Physician leaders share clinical insights on value-based therapy delivery, clinical trial access and integrated behavioral health in community oncology at major industry forumsCERRITOS, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Starling Oncology™, Inc. (NASDAQ: STLN), (“STLN” or the “Company”), one of the largest value-based community oncology groups in the United States, today highlighted its leadership team’s active season of industry engagement, recapping recent conference participation and p